Drug intelligence / Profile preview

miR-3619-5p mimic

Development stage
Preclinical
Lead developer
Kyoto Prefectural University of Medicine
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous
01

Overview

miR-3619-5p mimic is a synthetic double-stranded RNA molecule designed to mimic the endogenous tumor-suppressive microRNA miR-3619-5p. In esophageal squamous cell carcinoma (ESCC), miR-3619-5p levels are often depleted, leading to the overexpression of its target oncogene, PIM1 (proviral insertion site in Moloney murine leukemia virus 1). By restoring miR-3619-5p levels, the mimic directly binds to the 3' UTR of PIM1 mRNA, leading to its degradation or translational inhibition. This suppression results in reduced AKT phosphorylation, increased p21 expression, and subsequent inhibition of cell proliferation, migration, and invasion. Research conducted at the Kyoto Prefectural University of Medicine has demonstrated that systemic delivery of this mimic (e.g., via atelocollagen-complexed subcutaneous injection) can significantly inhibit tumor growth in xenograft models without significant systemic toxicity.

Other names
hsa-miR-3619-5p mimichsa-miR3619-5p mimichsa-miR 3619-5p mimicmicroRNA-3619-5p mimicmicroRNA3619-5p mimicmicroRNA 3619-5p mimic
02

Targets

CDK2 (Cyclin-dependent kinase 2)CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on miR-3619-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-3619-5p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call